TY - JOUR
T1 - Factors associated with non-remission in bipolar disorder
T2 - The multicenter treatment survey for bipolar disorder in psychiatric outpatient clinics (musubi)
AU - Tsuboi, Takashi
AU - Suzuki, Takefumi
AU - Azekawa, Takaharu
AU - Adachi, Naoto
AU - Ueda, Hitoshi
AU - Edagawa, Kouji
AU - Katsumoto, Eiichi
AU - Kubota, Yukihisa
AU - Goto, Eiichiro
AU - Hongo, Seiji
AU - Watanabe, Yoichiro
AU - Kato, Masaki
AU - Yasui-Furukori, Norio
AU - Yoshimura, Reiji
AU - Nakagawa, Atsuo
AU - Kikuchi, Toshiaki
AU - Watanabe, Koichiro
N1 - Funding Information:
Dr. Tsuboi has received consultant fees from Pfizer and speaker’s honoraria from Eli Lilly, Meiji-Seika Pharma, MSD, Janssen Pharmaceutical, Dainippon Sumitomo Pharma, Mitsubishi Tanabe Pharma, Yoshitomi Yakuhin, Mochida Pharmaceutical, Otsuka Pharmaceutical, Kyowa Pharmaceutical, and Takeda Pharmaceutical. Dr. Suzuki has received manuscript or speaker’s fees from Astellas, Dainippon Sumitomo Pharma, Eli Lilly, Elsevier Japan, Janssen Pharmaceuticals, Kyowa Yakuhin, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Novartis, Otsuka Pharmaceutical, Shionogi, Shire, Tsumura, Wiley Japan, and Yoshitomi Yakuhin, and research grants from Eisai, Mochida Pharmaceutical, Meiji Seika Pharma, and Shionogi. Dr. Azegawa has received speaker’s honoraria from Eli Lilly, Mochida Pharmaceutical Co, Ltd, Otsuka Pharmaceutical, and Pfizer. Dr. Ueda has received manuscript fees or speaker’s honoraria from Eli Lilly, Eisai Co. Ltd., Janssen Pharmaceutical, Meiji Seika Pharma, Mitsubishi Tanabe
Funding Information:
This study was supported by Ken Tanaka memorial research grant.
Publisher Copyright:
© 2020 Tsuboi et al.
PY - 2020
Y1 - 2020
N2 - Purpose: The aim of this study was to identify factors associated with non-remission in bipolar disorder. Patients and Methods: The multicenter treatment survey for bipolar disorder in psychiatric outpatient clinics (MUSUBI) study used a questionnaire administered at 176 clinics throughout Japan from September to October 2016. Clinic psychiatrists performed a retrospective medical record survey of consecutive cases with bipolar disorder. Patients were considered to be in remission if they met all of the following criteria: they were not in a mixed state, their manic or depressive symptoms were either borderline or nonexistent (corresponding to 2 or 1 points on the Clinical Global Impressions Scale, Bipolar Version), and their psychiatrists clinically considered them to be in remission. Enrolled patients were classified into remitters group and non-remitters group and demographic and clinical characteristics were contrasted between the groups. Non-remitters were compared with remitters, using a series of logistic regression analyses. Results: A total of 3130 patients (1420 men; mean age: 50.3 years) were included in this study; 1307 patients (41.8%) were in remission. Of the remaining 1823 patients, 1260 (40.3%) had mild to severe depression, 261 (8.3%) suffered from manic or hypomanic episodes, and 302 (9.6%) were in a mixed state. Logistic regression analyses found the following eight factors to be significantly correlated with non-remission in patients with bipolar disorder: female gender, younger age, unemployed status, rapid cycling pattern, comorbid alcohol/substance abuse, poorer social function, lithium non-use, and antidepressant use. Conclusion: The MUSUBI study, the largest nationwide investigation on bipolar disorder, identified eight clinically relevant factors associated with non-remission in bipolar patients. They have important clinical implications; further prospective studies are necessary to replicate these findings and to guide better managements for those in serious needs.
AB - Purpose: The aim of this study was to identify factors associated with non-remission in bipolar disorder. Patients and Methods: The multicenter treatment survey for bipolar disorder in psychiatric outpatient clinics (MUSUBI) study used a questionnaire administered at 176 clinics throughout Japan from September to October 2016. Clinic psychiatrists performed a retrospective medical record survey of consecutive cases with bipolar disorder. Patients were considered to be in remission if they met all of the following criteria: they were not in a mixed state, their manic or depressive symptoms were either borderline or nonexistent (corresponding to 2 or 1 points on the Clinical Global Impressions Scale, Bipolar Version), and their psychiatrists clinically considered them to be in remission. Enrolled patients were classified into remitters group and non-remitters group and demographic and clinical characteristics were contrasted between the groups. Non-remitters were compared with remitters, using a series of logistic regression analyses. Results: A total of 3130 patients (1420 men; mean age: 50.3 years) were included in this study; 1307 patients (41.8%) were in remission. Of the remaining 1823 patients, 1260 (40.3%) had mild to severe depression, 261 (8.3%) suffered from manic or hypomanic episodes, and 302 (9.6%) were in a mixed state. Logistic regression analyses found the following eight factors to be significantly correlated with non-remission in patients with bipolar disorder: female gender, younger age, unemployed status, rapid cycling pattern, comorbid alcohol/substance abuse, poorer social function, lithium non-use, and antidepressant use. Conclusion: The MUSUBI study, the largest nationwide investigation on bipolar disorder, identified eight clinically relevant factors associated with non-remission in bipolar patients. They have important clinical implications; further prospective studies are necessary to replicate these findings and to guide better managements for those in serious needs.
KW - Antipsychotics
KW - Bipolar disorder
KW - Mood stabilizer
KW - Nationwide study
KW - Non-remission
UR - http://www.scopus.com/inward/record.url?scp=85083109314&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083109314&partnerID=8YFLogxK
U2 - 10.2147/NDT.S246136
DO - 10.2147/NDT.S246136
M3 - Article
AN - SCOPUS:85083109314
SN - 1176-6328
VL - 16
SP - 881
EP - 890
JO - Neuropsychiatric Disease and Treatment
JF - Neuropsychiatric Disease and Treatment
ER -